Antipsychotic-induced tardive dyskinesia and polymorphic variations in COMT, DRD2, CYP1A2 and MnSOD genes: a meta-analysis of pharmacogenetic interactions (Q40136199)

From Wikidata

Jump to navigation Jump to search

scientific article published on 8 January 2008

Language	Label	Description	Also known as
English	Antipsychotic-induced tardive dyskinesia and polymorphic variations in COMT, DRD2, CYP1A2 and MnSOD genes: a meta-analysis of pharmacogenetic interactions	scientific article published on 8 January 2008

Statements

scholarly article

1 reference

Europe PubMed Central

17 September 2017

0 references

Antipsychotic-induced tardive dyskinesia and polymorphic variations in COMT, DRD2, CYP1A2 and MnSOD genes: a meta-analysis of pharmacogenetic interactions (English)

1 reference

Europe PubMed Central

17 September 2017

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

3

object named as

J van Os

1 reference

Europe PubMed Central

17 September 2017

author name string

P R Bakker

1

1 reference

Europe PubMed Central

17 September 2017

P N van Harten

2

1 reference

Europe PubMed Central

17 September 2017

language of work or name

0 references

publication date

8 January 2008

1 reference

Europe PubMed Central

17 September 2017

Molecular Psychiatry

1 reference

Europe PubMed Central

17 September 2017

13

1 reference

Europe PubMed Central

17 September 2017

5

1 reference

Europe PubMed Central

17 September 2017

544-556

1 reference

Europe PubMed Central

17 September 2017

https://scigraph.springernature.com/pub.10.1038/sj.mp.4002142

0 references

Neuroleptic-induced movement disorders: an overview

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002142

21 January 2018

Clinical implications of pharmacogenomics for tardive dyskinesia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002142

21 January 2018

Tardive drug-induced extrapyramidal syndromes

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002142

21 January 2018

Genetics and Epigenetics in Major Psychiatric Disorders

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002142

21 January 2018

Meta-analysis: principles and procedures

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002142

21 January 2018

Meta-Analysis. Potentials and promise

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002142

21 January 2018

Antipsychotic-induced tardive dyskinesia and the Ser9Gly polymorphism in the DRD3 gene: a meta analysis

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002142

21 January 2018

Tardive dyskinesia: who is at risk?

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002142

21 January 2018

Abnormal movements and tardive dyskinesia in smokers and nonsmokers with schizophrenia genotyped for cytochrome P450 2D6.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002142

21 January 2018

Pharmacogenetics for off-patent antipsychotics: reframing the risk for tardive dyskinesia and access to essential medicines

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002142

21 January 2018

Markers of glutamatergic neurotransmission and oxidative stress associated with tardive dyskinesia.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002142

21 January 2018

The genetics of schizophrenia: glutamate not dopamine?

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002142

21 January 2018

Schizophrenia genes, gene expression, and neuropathology: on the matter of their convergence

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002142

21 January 2018

Implications for atypical antipsychotics in the treatment of schizophrenia: neurocognition effects and a neuroprotective hypothesis

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002142

21 January 2018

A highly significant association between a COMT haplotype and schizophrenia.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002142

21 January 2018

A haplotype implicated in schizophrenia susceptibility is associated with reduced COMT expression in human brain

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002142

21 January 2018

Separate and interacting effects within the catechol-O-methyltransferase (COMT) are associated with schizophrenia.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002142

21 January 2018

COMT haplotypes suggest P2 promoter region relevance for schizophrenia.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002142

21 January 2018

Is COMT a susceptibility gene for schizophrenia?

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002142

21 January 2018

Tardive dyskinesia: possible involvement of free radicals and treatment with vitamin E.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002142

21 January 2018

A targeted mutation of the D3 dopamine receptor gene is associated with hyperactivity in mice

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002142

21 January 2018

D3 dopamine receptor mRNA is widely expressed in the human brain

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002142

21 January 2018

Association study of tardive dyskinesia and twelve DRD2 polymorphisms in schizophrenia patients

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002142

21 January 2018

Identification and characterization of ANKK1: a novel kinase gene closely linked to DRD2 on chromosome band 11q23.1

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002142

21 January 2018

Allelic association of the D2 dopamine receptor gene with receptor-binding characteristics in alcoholism

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002142

21 January 2018

D2 receptors binding potential is not affected by Taq1 polymorphism at the D2 receptor gene.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002142

21 January 2018

The A1 allele of the human D2 dopamine receptor gene predicts low D2 receptor availability in healthy volunteers.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002142

21 January 2018

Polymorphisms in the dopamine D2 receptor gene and their relationships to striatal dopamine receptor density of healthy volunteers.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002142

21 January 2018

Increased dopamine D2 receptor binding after long-term treatment with antipsychotics in humans: a clinical PET study

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002142

21 January 2018

D2 dopamine receptor gene in psychiatric and neurologic disorders and its phenotypes

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002142

21 January 2018

Advances in molecular genetics and the prevention and treatment of substance misuse: Implications of association studies of the A1 allele of the D2 dopamine receptor gene

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002142

21 January 2018

Functional analysis of the human D2 dopamine receptor missense variants

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002142

21 January 2018

A functional polymorphism in the promoter region of the dopamine D2 receptor gene is associated with schizophrenia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002142

21 January 2018

Association of seven polymorphisms of the D2 dopamine receptor gene with brain receptor-binding characteristics

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002142

21 January 2018

Functional significance of a C-->A polymorphism in intron 1 of the cytochrome P450 CYP1A2 gene tested with caffeine

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002142

21 January 2018

A functional polymorphism of the cytochrome P450 1A2 (CYP1A2) gene: association with tardive dyskinesia in schizophrenia.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002142

21 January 2018

Genetic association analysis of functional polymorphisms in the cytochrome P450 1A2 (CYP1A2) gene with tardive dyskinesia in Japanese patients with schizophrenia.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002142

21 January 2018

Association between the MnSOD Ala-9Val polymorphism and development of schizophrenia and abnormal involuntary movements in the Xhosa population

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002142

21 January 2018

On signal sequence polymorphisms and diseases of distribution

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002142

21 January 2018

Structural dimorphism in the mitochondrial targeting sequence in the human manganese superoxide dismutase gene. A predictive evidence for conformational change to influence mitochondrial transport and a study of allelic association in Parkinson's di

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002142

21 January 2018

The Ala16Val genetic dimorphism modulates the import of human manganese superoxide dismutase into rat liver mitochondria

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002142

21 January 2018

Tardive dyskinesia is not associated with the polymorphisms of 5-HT2A receptor gene, serotonin transporter gene and catechol-o-methyltransferase gene ⋆

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002142

21 January 2018

Negative association between catechol-O-methyltransferase (COMT) gene Val158Met polymorphism and persistent tardive dyskinesia in schizophrenia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002142

21 January 2018

Polymorphisms of dopamine degradation enzyme (COMT and MAO) genes and tardive dyskinesia in patients with schizophrenia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002142

21 January 2018

Pharmacogenomics in schizophrenia: the quest for individualized therapy.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002142

21 January 2018

Polymorphisms of dopamine receptors and tardive dyskinesia among Chinese patients with schizophrenia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002142

21 January 2018

Polymorphic variations in GSTM1, GSTT1, PgP, CYP2D6, CYP3A5, and dopamine D2 and D3 receptors and their association with tardive dyskinesia in severe mental illness

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002142

21 January 2018

Tardive dyskinesia and DRD2, DRD3, DRD4, 5-HT2A variants in schizophrenia: an association study with repeated assessment

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002142

21 January 2018

Relationship between adverse effects of antipsychotic treatment and dopamine D(2) receptor polymorphisms in patients with schizophrenia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002142

21 January 2018

Association between three functional polymorphisms of dopamine D2 receptor gene and tardive dyskinesia in schizophrenia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002142

21 January 2018

Association of dopaminergic and serotonergic genes with tardive dyskinesia in patients with chronic schizophrenia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002142

21 January 2018

Comparative metabolic capabilities and inhibitory profiles of CYP2D6.1, CYP2D6.10, and CYP2D6.17

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002142

21 January 2018

The increased activity of plasma manganese superoxide dismutase in tardive dyskinesia is unrelated to the Ala-9Val polymorphism.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002142

21 January 2018

Association between Ala-9Val polymorphism of Mn-SOD gene and schizophrenia.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002142

21 January 2018

Pharmacogenetics and pharmacogenomics of schizophrenia: a review of last decade of research

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002142

21 January 2018

Glutamate and schizophrenia: beyond the dopamine hypothesis

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002142

21 January 2018

Combined analysis of 635 patients confirms an age-related association of the serotonin 2A receptor gene with tardive dyskinesia and specificity for the non-orofacial subtype

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002142

21 January 2018

Pharmacogenetics of tardive dyskinesia: combined analysis of 780 patients supports association with dopamine D3 receptor gene Ser9Gly polymorphism

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002142

21 January 2018

Lower risk for tardive dyskinesia associated with second-generation antipsychotics: a systematic review of 1-year studies

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002142

21 January 2018

Randomized controlled trial of the effect on Quality of Life of second- vs first-generation antipsychotic drugs in schizophrenia: Cost Utility of the Latest Antipsychotic Drugs in Schizophrenia Study (CUtLASS 1).

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002142

21 January 2018

Effectiveness of antipsychotic drugs in patients with chronic schizophrenia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002142

21 January 2018

Simultaneous prescribing of atypical antipsychotics, conventional antipsychotics and anticholinergics-a European study

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002142

21 January 2018

Pharmacogenetics of psychotropic drug response

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002142

21 January 2018

A new era in psychiatric genetics?

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002142

21 January 2018

Shifting emphasis from pharmacogenomics to theragnostics

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002142

21 January 2018

A road map for efficient and reliable human genome epidemiology

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002142

21 January 2018

Lack of association between a functional polymorphism of the cytochrome P450 1A2 (CYP1A2) gene and tardive dyskinesia in schizophrenia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002142

21 January 2018

CYP2D6 polymorphisms and the risk of tardive dyskinesia in schizophrenia: a meta-analysis.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002142

7 January 2021

based on heuristic

inferred from DOI database lookup

Genetic susceptibility to tardive dyskinesia in chronic schizophrenia subjects: III. Lack of association of CYP3A4 and CYP2D6 gene polymorphisms

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002142

7 January 2021

based on heuristic

inferred from DOI database lookup

Genetic susceptibility to tardive dyskinesia in chronic schizophrenia subjects: I. Association of CYP1A2 gene polymorphism

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002142

7 January 2021

based on heuristic

inferred from DOI database lookup

D2 dopamine receptor gene (DRD2) Taq1 A polymorphism: reduced dopamine D2 receptor binding in the human striatum associated with the A1 allele.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002142

7 January 2021

based on heuristic

inferred from DOI database lookup

Association of CYP2D6 and CYP1A2 gene polymorphism with tardive dyskinesia in Chinese schizophrenic patients

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002142

7 January 2021

based on heuristic

inferred from DOI database lookup

Genetic polymorphism in the 5'-flanking region of human CYP1A2 gene: effect on the CYP1A2 inducibility in humans

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002142

7 January 2021

based on heuristic

inferred from DOI database lookup

The manganese superoxide dismutase Ala16Val dimorphism modulates both mitochondrial import and mRNA stability.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002142

7 January 2021

based on heuristic

inferred from DOI database lookup

Genetic susceptibility to tardive dyskinesia among schizophrenia subjects: IV. Role of dopaminergic pathway gene polymorphisms

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002142

7 January 2021

based on heuristic

inferred from DOI database lookup

Association of TaqI A polymorphism of dopamine D2 receptor gene and tardive dyskinesia in schizophrenia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002142

7 January 2021

based on heuristic

inferred from DOI database lookup

Association between neuroleptic drug-induced extrapyramidal symptoms and dopamine D2-receptor polymorphisms in Japanese schizophrenic patients.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002142

7 January 2021

based on heuristic

inferred from DOI database lookup

Antipsychotic-induced extrapyramidal symptoms in patients with schizophrenia: associations with dopamine and serotonin receptor and transporter polymorphisms

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002142

7 January 2021

based on heuristic

inferred from DOI database lookup

The human dopamine receptor D2 (DRD2) gene is associated with tardive dyskinesia in patients with schizophrenia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002142

7 January 2021

based on heuristic

inferred from DOI database lookup

Polymorphisms in dopamine receptor DRD1 and DRD2 genes and psychopathological and extrapyramidal symptoms in patients on long-term antipsychotic treatment

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002142

7 January 2021

based on heuristic

inferred from DOI database lookup

Manganese superoxide dismutase gene polymorphism and schizophrenia: relation to tardive dyskinesia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002142

7 January 2021

based on heuristic

inferred from DOI database lookup

Comments on "Association between Ala-9Val polymorphism of MnSOD gene and schizophrenia" by O. Akyol et al. Progress in Neuropsychopharmacology and Biological Psychiatry 29, 2005, 123-131

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002142

7 January 2021

based on heuristic

inferred from DOI database lookup

Neurobiology of schizophrenia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002142

7 January 2021

based on heuristic

inferred from DOI database lookup

Antipsychotic polypharmacy: a survey of discharge prescriptions from a tertiary care psychiatric institution

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002142

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1038/SJ.MP.4002142

1 reference

Europe PubMed Central

17 September 2017

1 reference

Europe PubMed Central

17 September 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q40136199&oldid=1886500765"